КОАГУЛЯЦИОННЫЕ МЕХАНИЗМЫ ПРИ СЕПСИСЕ (СОВРЕМЕННЫЕ МЕТОДЫ ПАТОГЕНЕТИЧЕСКОЙ ТЕРАПИИ). Часть II
Аннотация
В данном обзоре литературы подробно рассмотрены основные звенья патогенеза нарушений гемостаза при сепсисе. Описаны применяемые методы диагностики и коррекции коагуляционных нарушений у септических больных. Охарактеризовано также влияние экстракорпоральных методик на систему гемостаза (плазмаферез, гемосорбция, МОК и др.). Проведенный анализ литературы свидетельствует о необходимости совершенствования существующих и поиска новых методик антикоагулянтной терапии сепсиса.
Литература
Воинов, В. А. Мембранный Плазмаферез: рекомендации для врачей / В.А. Воинов. - Москва: Трекпор Технолоджи, 2004. - 270 c.
Влияние гемосорбции на состояние системы гемостаза у больных с сепсисом / Н.Г. Кручинский [и др.] // Хирургия. - 1997. - № 7. - C. 44-47.
Спас, В.В. Респираторный дистресс-синдром взрослых / В.В. Спас, Р.Э. Якубцевич. - Минск: Ипати, 2007. - 203 с.
Якубцевич, Р.Э. Коррекция коагуляционных нарушений с помощью магнитной обработки крови у больных с острым респираторным дистресс-синдромом при сепсисе / Р.Э. Якубцевич, В.В. Спас, П.А. Герасимчик // Вест. Интенс. Терапии. - 2005. - № 6. - С. 112-114.
A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1 / W. Li [et al.] // J. Immunol. - 2007. - Vol. 178, № 6. - P 3856-3864.
Aird, W.C. Natural anticoagulant inhibitors: activated Protein C / W.C. Aird // Best Pract. Res. Clin. Haematol. - 2004. - Vol. 17. - P. 161-182.
Al-Arrayed, S. Use of low molecular weight heparin for hemodialysis: a short-term study / S. Al-Arrayed, R. Seshadri // Saudi J. Kidney Dis Transpl. - 2002. - Vol. 13, № 2. - P. 146-150.
Amanzadeh, J. Anticoagulation and continuous renal replacement therapy / J. Amanzadeh, R.F. Reilly // Semin. Dial. - 2006. - Vol. 19, № 4. - P. 311-316.
Angus D.C. Epidemiology of sepsis: an update / D.S. Angus, R.S. Wax // Crit. Care Med. - 2001. - Vol. 29. - P. 109-116.
Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood / P.J. Souter [et al.] // Crit. Care Med. - 2001. - Vol. 29. - P. 134-139.
Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells / C. Oelschlager [et al.] // Blood. - 2002. - Vol. 99. - P. 4015-4020.
Antithrombin, heparin, and heparan sulfate / S.M. Opal [et al.] // Crit. Care Med. - 2002. - Vol. 30, № 5. - P. 325-331.
Application of clexane in urosepsis: necessity or the issue of fashion / L.V. Usenko [et al.] // Klin. Khir. - 2001. - Vol. № 6. - P. 54-57.
ARDSNET. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. // N. Engl. J. Med. - 2000.- Vol. 342.- P. 13011308.
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. // Lancet. - 1996.- Vol. 348, № 9038.- P. 1329-1339.
Aspirin inhibits serine phosphorylation of IRS-1 in muscle and adipose tissue of septic rats / G.C. Barreieo [et al.] // Biochem. Biophys. Res. Commun. - 2004. - Vol. 320, № 3. - P. 992-997.
Aspirin treatment is associated with a significantly decreased risk of Staphylococcus aureus bacteremia in hemodialysis patients with tunneled catheters / M. Sedlacek [et al.] // Am. J. Kidney Dis. - 2007. - Vol. 49, № 3. - P. 401-408.
Bhatt, D. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes / D. Bhatt, E. Topol // J.A.M.A. - 2000. - Vol. 284. - P. 1549-1558.
Burden of illness imposed by severe sepsis in Germany / A. Schmid [et al.] // Eur. J. Hlth Econom. - 2002. - Vol. 3. - P. 77-82.
Cade, J.F. High risk of the critically ill for venous thromboembolism / J.F. Cade // Crit. Care Med. - 1982. - Vol. 10. - P. 448-450.
Coagulation blockade prevents sepsisinduced respiratory and renal failure in baboons / K.E. Welty-Wolf [et al.] // Am. J. Respir. Crit. Care Med. - 2001. - Vol. 164, № 10, Pt 1. - P. 1988-1996.
Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients / J. Maiyszko [et al.] // Am. J. Nephrol. - 2004. - Vol. 24, № 6. - P. 624-629.
Critical roles of platelets in lipopolysaccharide-induced lethality: effects of glycyrrhizin and possible strategy for acute respiratory distress syndrome / Z. Yu [et al.] // Int. Immunopharmacol. - 2005. - Vol. 5, № 3. - P. 571-580.
Crowther, M.A. Continuing challenges of sepsis research / M.A. Crowther, J.C. Marshall // J.A.M.A. - 2001. - Vol. 286. - P 1894 - 1896.
Davies H. Anticoagulation in CRRT: agents and strategies in Australian ICUs / H. Davies, G. Leslie // Aust. Crit. Care. - 2007. - Vol. 20, № 1. - P. 15-26.
Deaths: final data for 1999 / D. L. Hoyert [et al.] // National Vital Statisties Reports. - 2001. - Vol. 49, № 8. - P 111-113.
Deep vein thrombosis and its prevention in critically ill adults / J. Attia [et al.] // Arch. Intern. Med. - 2001. - Vol. 161. - P. 12681279.
DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage / F.B. Taylor Jr [et al.] // Blood. - 1991. - Vol. 78. - P 364-368.
Early goal-directed therapy in the treatment of severe sepsis and septic shock / E. Rivers [et al.] // N. Engl. J. Med. - 2001. - Vol. 345. - P. 1368-1377.
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock / D. Annane [et al.] // J.A.M.A. - 2002. - Vol. 288. - P. 862-871.
Efficacy and safety of recombinant human activated protein C for severe sepsis / G.R. Bernard [et al.] // N. Engl. J. Med. - 2001. - Vol. 344. - P. 699-709.
Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia / T. E. Emerson Jr [et al.] // Am. J. Med. - 1989. - Vol. 87. - P. 27-33.
Enoxaparin inhibits fibrin sheath formation and decreases central venous catheter colonization following bacteremic challenge / J.E. Keller [et al.] // Crit. Care Med. - 2006. - Vol. 34, № 5. - P. 1450-1455.
Enoxaparin-induced skin necrosis: a fatal outcome / S. Singh [et al.] // Am. J. Ther. - 2007. - Vol. 14, № 4. - P. 408-410.
Grinnell, B.W. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis / B.W. Grinnell, D. Joyce // Crit. Care Med. - 2001. - Vol. 29, № 7. - P 53-60.
Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor-alpha production in human monocytes / M Heinzelmann [et al.] // Ann. Surg. - 1999. - Vol. 229, № 4. - P. 542550.
Intensive insulin therapy in the critically ill patients / G. van den Berghe [et al.] // N. Engl. J. Med. - 2001. - Vol. 345. - P. 13591 3 67.
In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes / A. Isla [et al.] // Clin. Ther. - 2005 Sep. - Vol. 27, № 9. - P. 1444-1451.
Marshall, J.C. Clinical trials of mediator-directed therapy in sepsis: what have we learned? / J.C. Marshall // Intensive Care Med. - 2000. - Vol. 26, № 1. - P. 75-83.
Natanson, C. The sirens' songs of confirmatory sepsis trials: selection bias and sampling error / C. Natanson, C.J. Esposito, S.M. Banks // Crit. Care Med. - 1998. - Vol. 26. - P. 1927-1931.
Naumnik, B. Unfractionated Heparin but Not Enoxaparin Causes Delayed Plasma PAI-1 Depletion in Hemodialysis Patients: A Prospective Study / B. Naumnik, K. Pawlak, M. Mysliwiec // Clin. Appl. Thromb. Hemost. - 2007. - P. 25.
New strategies for clinical trials in patients with sepsis and septic shock / J. Cohen [et al.] // Crit. Care Med. - 2001. - Vol. 29. - P. 880-886.
Prolonged shock in the baboon subj ected to infusion of E. coli endotoxin / J.J. Coalson [et al.] // Circ. Shock. - 1978. - Vol. 5. - P. 423 - 437.
Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon / F.B. Taylor Jr // J. Clin. Invest. - 1987. - Vol. 79. - P. 918-925.
Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis / P.Q. Eichacker [et al.] // Am. J. Respir. Crit. Care Med. - 2002. - Vol. 166. - P. 11971205.
Sabloff, M. The effect of plasmapheresis on the serum activity level of dalteparin: a case report / M. Sabloff, P.S. Wells // Blood Coagul. Fibrinolysis. - 2000. - Vol. 11, № 4. - P 395-400.
Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post- certification study / R. Klingel [et al.] // Kidney Blood Press. Res. - 2004. - Vol. 27, № 4. - P. 211-217.
Tej edor Alonso, M. A. Thrombocytopenia and anaphylaxis secondary to heparin in a hemodialysis patient / M.A. Tejedor Alonso // Clin. Nephrol. - 2005. - Vol. 63, № 3. - P. 236-240.
The natural history of the systemic inflammatory response syndrome (SIRS):a prospective study / M.S. Rangel-Frausto [et al.] // J.A.M.A. - 1995. - Vol. 273. - P. 117-123.
Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock / A.A. Creasey [et al.] // J. Clin. Invest. - 1993. - Vol. 91. - P. 2850-2856.
Wheeler, A. P. Treating patients with severe sepsis / A. P. Wheeler, G. R. Bernard // N. Engl. J. Med. - 1999. - Vol. 340. - P. 207-214.
Zeni, F Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment / F. Zeni, B. Freeman, C. Natanson // Crit. Care Med. - 1997. - Vol. 25. - P. 1095-1100.
